^
    1m
    AREN0533: Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor (clinicaltrials.gov)
    P3, N=395, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2025 --> Mar 2026
    Trial completion date
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • dactinomycin • Marqibo (vincristine liposomal)
    1m
    Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy (clinicaltrials.gov)
    P1, N=29, Completed, Therapeutic Advances in Childhood Leukemia Consortium | Recruiting --> Completed | Trial completion date: Dec 2022 --> Dec 2024
    Trial completion • Trial completion date
    |
    methotrexate • Marqibo (vincristine liposomal)
    2ms
    Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, Medical College of Wisconsin | N=33 --> 11 | Trial completion date: May 2026 --> Oct 2027 | Trial primary completion date: May 2026 --> May 2025 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Rituxan (rituximab) • cyclophosphamide • etoposide IV • pegylated liposomal doxorubicin • vincristine • prednisone • Zynlonta (loncastuximab tesirine-lpyl) • Marqibo (vincristine liposomal)
    4ms
    NCI-2018-01198: Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia (clinicaltrials.gov)
    P2, N=42, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2025 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • bortezomib • cyclophosphamide • etoposide IV • clofarabine • Arzerra (ofatumumab) • Truxima (rituximab-abbs) • Marqibo (vincristine liposomal) • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    6ms
    ECOG-ACRIN EA9152: Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=74, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial primary completion date: Dec 2028 --> Dec 2025
    Trial primary completion date • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • vincristine • Marqibo (vincristine liposomal)
    7ms
    AREN0533: Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor (clinicaltrials.gov)
    P3, N=395, Active, not recruiting, Children's Oncology Group
    Trial completion date
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • dactinomycin • Marqibo (vincristine liposomal)
    11ms
    Phase I/II clinical study of rituximab combined with cyclophosphamide, Mitoxantrone hydrochloride liposome, vincristine and prednisone in the treatment of newly diagnosed large B-cell lymphoma with bulky disease (ChiCTR2400093033)
    P4, N=51, Recruiting, The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University
    New P4 trial
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    Rituxan (rituximab) • cyclophosphamide • prednisone • Marqibo (vincristine liposomal) • Duoenda (mitoxantrone liposomal)
    1year
    ECOG-ACRIN EA9152: Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=74, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 expression
    |
    Venclexta (venetoclax) • vincristine • Marqibo (vincristine liposomal)
    over1year
    Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas (clinicaltrials.gov)
    P1, N=8, Terminated, National Cancer Institute (NCI) | Completed --> Terminated; The study was terminated early because copanlisib was removed from the market by the Food and Drug Administration (FDA) and the manufacturer.
    Trial termination
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Aliqopa (copanlisib) • vincristine • Marqibo (vincristine liposomal)
    over1year
    OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine (clinicaltrials.gov)
    P3, N=1152, Completed, Universität des Saarlandes | Active, not recruiting --> Completed | Trial completion date: May 2025 --> Jan 2024 | Trial primary completion date: May 2025 --> Jan 2024
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy • FDG PET
    |
    ALK (Anaplastic lymphoma kinase) • CD20 (Membrane Spanning 4-Domains A1)
    |
    ALK positive
    |
    Rituxan (rituximab) • cyclophosphamide • Marqibo (vincristine liposomal)
    almost2years
    Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=33, Recruiting, Medical College of Wisconsin | Trial completion date: May 2028 --> May 2026 | Trial primary completion date: May 2027 --> May 2026
    Trial completion date • Trial primary completion date • Combination therapy
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    MYC rearrangement • BCL6 rearrangement
    |
    Rituxan (rituximab) • cyclophosphamide • etoposide IV • pegylated liposomal doxorubicin • vincristine • prednisone • Zynlonta (loncastuximab tesirine-lpyl) • Marqibo (vincristine liposomal)
    over2years
    OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine (clinicaltrials.gov)
    P3, N=1152, Active, not recruiting, Universität des Saarlandes | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: Dec 2023 --> May 2025
    Trial completion date • Trial primary completion date • Combination therapy • FDG PET
    |
    ALK (Anaplastic lymphoma kinase) • CD20 (Membrane Spanning 4-Domains A1)
    |
    ALK positive
    |
    Rituxan (rituximab) • cyclophosphamide • Marqibo (vincristine liposomal)